多发性骨髓瘤中枢神经系统浸润1例及文献复习  

Central nervous system infiltration in multiple myeloma:a case report and literature review

作　　者：张萌 沈元元[1] 董毅 ZHANG Meng;SHEN Yuanyuan;DONG Yi(Department of Hematology,the Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230601,China)

机构地区：[1]安徽医科大学第二附属医院血液科,安徽合肥230601

出　　处：《现代医药卫生》2024年第23期4041-4046,共6页Journal of Modern Medicine & Health

基　　金：安徽省重点研究与开发计划项目(202104j07020030)。

摘　　要：回顾性分析该院血液科收治的1例多发性骨髓瘤(MM)中枢神经系统(CNS)浸润(CNS-MM)患者的临床资料及治疗措施。患者,男,61岁。疾病诊断时分期较晚且伴高危遗传学,有发生CNS-MM的高危特征,既往使用CD38单抗及泊马度胺等多线治疗后多次复发,累及CNS。入院后选择塞利尼索、苯达莫司汀、地塞米松进行全身化疗,同时加用氨甲蝶呤、阿糖胞苷、地塞米松三联腰穿鞘内注射,维持疾病无进展生存近12个月,总生存期已达58个月。以塞利尼索为基础方案可有效治疗CNS-MM,这为临床提供了一定的借鉴意义。The clinical data and treatment of a case of multiple myeloma(MM)with central nervous system(CNS)infiltration(CNS-MM)admitted to the Department of Hematology of the hospital were retrospectively analyzed.A 61-year-old male patient with the a late stage and accompanied by high-risk genetics at the time of diagnosis had the high-risk characteristics of CNS-MM.After previous multi-line treatment with CD38 monoclonal antibody and pomalidomide,the patient had multiple recurrences involving the CNS.After admission,selinexor,bendamustine and dexamethasone were selected for systemic chemotherapy.At the same time,methotrexate,cytarabine and dexamethasone were injected intrathecally to maintain the progression-free survival of the disease for nearly 12 months,and the overall survival has reached 58 months.The selinexor-based can effectively treat CNS-MM,and the successful diagnosis and treatment provide a certain reference for clinical practice.

关 键 词：中枢神经系统 多发性骨髓瘤 浸润 病例报告 

分 类 号：R733.3[医药卫生—肿瘤]